Pharmacotherapy: Biosimilar switching - "To set a form upon desired change"

Affiliations

¹ Division of Rheumatology, Department of Medicine, UMass Memorial Medical Centre and University of Massachusetts Medical School, 119 Belmont Street, Worcester, Massachusetts 01605, USA.
² School of Public Health and School of Medicine, Oregon Health &Science University, GH104, 3375 SW Terwilliger Blvd, Portland, Oregon 97239, USA.

Comment

Jonathan Kay et al. Nat Rev Rheumatol. 2017 Jul.

. 2017 Jul;13(7):391-392.

doi: 10.1038/nrrheum.2017.79. Epub 2017 Jun 1.

¹ Division of Rheumatology, Department of Medicine, UMass Memorial Medical Centre and University of Massachusetts Medical School, 119 Belmont Street, Worcester, Massachusetts 01605, USA.
² School of Public Health and School of Medicine, Oregon Health &Science University, GH104, 3375 SW Terwilliger Blvd, Portland, Oregon 97239, USA.

No abstract available

Comment on

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.